GLP-2 TRZ Dual Agonist: A Plain-English Research Guide
On this page
What is GLP-2 TRZ?
GLP-2 TRZ is a dual receptor agonist: a single peptide that activates two hormone receptors involved in blood sugar and appetite. Those are the receptors for GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). The “2” in its name refers to those two receptors.
GLP-2 TRZ is a 39-amino-acid peptide based on the GIP sequence, with a fatty-acid side chain that binds albumin in the blood. That slows its clearance and gives it a half-life of about five days in clinical studies.15 It went through full pharmaceutical development and has a large body of clinical trial data.23
GLP-2 TRZ is a single peptide that activates both the GIP and GLP-1 receptors, studied in research on blood sugar control, body weight and receptor pharmacology. Full Scale Peptides supplies it as a freeze-dried powder with a published COA, for research use only.
GLP-2 TRZ at a glance
Receptors activated
GIP and GLP-1, the two main “incretin” hormones released after meals.
Amino acids
Based on the GIP sequence, with a fatty-acid chain for a long half-life.
Phase 3 weight change
Mean body-weight reduction at the highest dose after 72 weeks in the SURMOUNT-1 trial.
Our current lot
HPLC purity for lot FSP-TIRZ10-0326-A, with identity confirmed by LC-MS.
The incretin system, explained simply
After a meal, the gut releases two hormones called incretins, GIP and GLP-1. Both tell the pancreas to release insulin, but only when blood sugar is high. GLP-1 also slows stomach emptying and signals fullness to the brain, while GIP is studied for its role in fat-tissue metabolism.
Earlier research compounds activated only the GLP-1 receptor. GLP-2 TRZ was designed to activate both, on the idea that the two signals together could do more than either alone.
What makes it unusual: an “imbalanced” agonist
GLP-2 TRZ doesn't activate both receptors equally. Detailed pharmacology work showed it is imbalanced, acting more like natural GIP at the GIP receptor while being weaker at the GLP-1 receptor. At the GLP-1 receptor it is also biased: it favors one signaling route inside the cell (cAMP) over another (β-arrestin), which leads to less receptor internalization.1 Researchers think this signaling profile may be part of why it behaves differently from pure GLP-1 agonists.
What the clinical research shows
- Type 2 diabetes (SURPASS-2). In a 40-week head-to-head trial, all three doses lowered HbA1c more than the GLP-1 agonist semaglutide at 1 mg, and produced greater weight loss.2
- Obesity (SURMOUNT-1). In a 72-week trial in adults with obesity, mean body-weight reductions were 15.0%, 19.5% and 20.9% at the three doses, compared with 3.1% with placebo.3
- Mechanism reviews. Recent reviews describe how the two receptors contribute to effects on insulin, glucagon, appetite and fat metabolism.45
The clinical results above come from pharmaceutical trials run under medical supervision. They describe the approved medicine, not the research-grade material we supply, and nothing on this page describes or supports use in people or animals.
Most side effects reported in the trials were gastrointestinal and dose-related, and results depend heavily on dose-escalation design. Research-grade material shares the molecule, not the pharmaceutical manufacturing process, which is exactly why lot-level testing matters.
GLP-2 TRZ 10mg, research grade
Freeze-dried powder with a third-party COA published before you buy, and tracked U.S. shipping. For laboratory research use only.
Purity and testing: why the COA matters
A 39-amino-acid peptide with a fatty-acid side chain is complex to make, and truncated or incompletely modified versions are a real risk. Every lot from Full Scale Peptides is tested by an independent lab, Freedom Diagnostics, before it is sold. HPLC measures purity, LC-MS confirms the molecular identity, and the full report is published before you buy.
- Lot
- FSP-TIRZ10-0326-A
- Tested
- May 27, 2026
- Lab
- Freedom Diagnostics
- Measured content
- 11.71 mg (10 mg labeled)
- Accession #
- 2605260162
- Report
- View full COA
New to reading lab reports? See how to read and verify a Certificate of Analysis and why 99%+ purity matters in research.
How GLP-2 TRZ is handled in the lab
GLP-2 TRZ ships as a lyophilized (freeze-dried) powder, meaning the water has been removed to keep the peptide stable. Store sealed vials at −20 °C, protected from light. Before use in research it is reconstituted, or dissolved back into a liquid, usually with bacteriostatic water. Handling it the same careful way every time keeps results consistent:
- Let the sealed vial come to room temperature before opening it, to limit condensation.
- Add the water slowly down the inside wall of the vial, not directly onto the powder.
- Swirl gently until the powder is fully dissolved. Don’t shake it.
- Label the vial with the date, keep it refrigerated at 2–8 °C away from light, and avoid repeated freeze–thaw cycles.
For more detail, see our reconstitution guide and storage and handling best practices.
Key takeaways
- GLP-2 TRZ is a dual GIP/GLP-1 receptor agonist; the “2” refers to its two receptors.
- It is a 39-amino-acid peptide with a fatty-acid chain that gives it a half-life of about five days.
- It is imbalanced and biased: GIP-like at the GIP receptor, weaker and signaling-biased at the GLP-1 receptor.
- Phase 3 trials reported mean weight reductions of up to 20.9% at 72 weeks and strong blood-sugar results.
- Our current lot tests at 99.89% purity, with identity confirmed by LC-MS and the full COA published. For laboratory research use only.
Frequently asked questions
Is GLP-2 TRZ the same as the hormone GLP-2?
No. The “2” in GLP-2 TRZ refers to its two target receptors (GIP and GLP-1). GLP-2 is a separate gut hormone with a different receptor and different effects.
How is GLP-2 TRZ different from a GLP-1 agonist?
A GLP-1 agonist activates one receptor. GLP-2 TRZ activates both the GIP and GLP-1 receptors, and its GIP activity is actually the stronger of the two.
How is it different from GLP-3R?
GLP-2 TRZ activates two receptors (GIP and GLP-1). GLP-3R adds a third, the glucagon receptor. See our GLP-3R guide.
What purity is Full Scale Peptides' GLP-2 TRZ?
The current lot (FSP-TIRZ10-0326-A) measured 99.89% purity by HPLC, with identity confirmed by LC-MS at Freedom Diagnostics. The full Certificate of Analysis is published in our COA library.
How is it supplied and stored?
It ships as a 10 mg lyophilized powder in a sealed glass vial. Store unopened vials at −20 °C away from light. Once reconstituted, keep the vial refrigerated at 2–8 °C.
Is it for human or veterinary use?
No. The material we supply is sold strictly for laboratory research. It is not for human or veterinary use and must not be administered to people or animals.
Scientific references
The findings summarized on this page come from published scientific literature, available on PubMed. Full Scale Peptides did not conduct, fund or sponsor this research, and nothing here implies endorsement by the authors or their institutions. The studies describe research on dual GIP/GLP-1 receptor agonists itself, not the product we supply.
- Willard FS, Douros JD, Gabe MB, et al. JCI Insight. 2020;5(17). PMID: 32730231
- FrÃas JP, Davies MJ, Rosenstock J, et al. N Engl J Med. 2021;385(6):503–515. PMID: 34170647
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022;387(3):205–216. PMID: 35658024
- Galindo RJ, Cheng AYY, Longuet C, et al. Diabetes Ther. 2026;17(1):19–40. PMID: 41196501
- Avgerinos I, Kakotrichi P, Karagiannis T, et al. Expert Opin Drug Discov. 2024;19(5):511–522. PMID: 38654653
Continue your research
For laboratory research use only. Not for human or veterinary use. The information on this page is provided for educational purposes and describes published research; it is not medical advice, and no statement here has been evaluated by the FDA.